Furthermore, durable clinical responses were obtained when PBMC-derived tumor-reactive T cells, comprising almost exclusively clonally expressed neoepitope-specific CD8+ and CD4+ T cells, were infused (10, 11, 16). This evidence concerns the gene CD8A and neoplasm.